Physician profile
Krishna Patel
NPI 1902457518
$3,067.50
in general payments reported to CMS, 2019-2025
37 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $611 · 2023: $740 · 2024: $576 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.59 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $472.08 | 2021-2025 | |
| Abbvie INC. | $375.59 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $292.29 | 2021-2023 | |
| Lilly USA, LLC | $231.51 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $141.89 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.12 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $91.29 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $84.97 | 2021-2024 | Arexvy, Bexsero, Shingrix |
| Esperion Therapeutics, INC. | $71.34 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.46 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.63 | 2024 | Jardiance |
| Sanofi Pasteur INC. | $41.15 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $37.31 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.75 | 2023-2024 | Xarelto |
| Cardiovascular Systems INC. | $26.81 | 2022 | |
| Teleflex LLC | $26.64 | 2024 | Urolift |
| Shield Therapeutics INC | $25.45 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.82 | 2023 | Rexulti |
| Mylan Specialty L.P. | $21.76 | 2021 | |
| Viiv Healthcare Company | $20.86 | 2025 | Apretude |
| Cequr Corporation | $20.45 | 2024-2025 | Cequr Simplicity |
| Collegium Pharmaceutical, INC. | $19.04 | 2023 | Xtampza |
| Seqirus USA INC | $18.74 | 2021 | |
| Scynexis, INC. | $18.05 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.04 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.93 | 2021 | |
| Dexcom, INC. | $15.27 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $13.98 | 2023 | Gardasil 9, Proquad, Vaxneuvance |
| Amarin Pharma, INC. | $13.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.67 | 2023 | |
| Hikma Pharmaceuticals USA | $13.26 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.26 | 2021 | |
| Mannkind Corporation | $13.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.